Recently, the study involving 41 MDS patients that were sequenced before and after the progression to AML [10] indicated that mutations in genes encoding ASXL1, RUNX1, and TP53 were often present in post-progression samples albeit the statistical power of these data was quite limited in such type of study. The gene discussed is TP53; the disease is acute myeloid leukemia.